Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Seragon

- PMLiVE

Merck and Advaxis to study anti-PD1 combo

Collaboration to investigate pembrolizumab and ADXS-PSA in prostate cancer

- PMLiVE

Illumina partners with pharma majors on cancer diagnostic

Will work with AstraZeneca, Janssen and Sanofi to develop gene sequencing tool

- PMLiVE

Chugai soars on Roche buyout rumours

Reports circulating that Swiss company is poised to make $10bn offer

- PMLiVE

Avastin gets US green light for late-stage cervical cancer

Fifth oncology indication for Roche’s medicine

- PMLiVE

Roche blasts UK’s ‘broken’ HTA system as Kadcyla rejected

But NICE says it is 'very disappointed' with the company's pricing policy

- PMLiVE

Roche’s Avastin gets new EU nod in ovarian cancer

Wins new approval for hard-to-treat platinum-resistant recurrent form of disease

Roche Basel Switzerland

Roche pays $450m for ‘gene-silencing’ firm Santaris Pharma

Deal marks major return to the RNAi field it exited four years ago

Roche - Basel

Roche wins European approval for new leukaemia drug

Gazyvaro now available for use in treatment of blood cancer in the EU

- PMLiVE

AZ signs two companion diagnostic deals

Will help identify patients suitable for treatment with lung cancer drugs

- PMLiVE

Two blood cancer drugs among CHMP recommendations

Five new drugs, including Janssen’s Imbruvica and Gilead’s Zydelig, backed for use in Europe

- PMLiVE

Nexavar fails late-stage breast cancer trial

Bayer’s oncology drug unable to improve progression free survival in new indication

- PMLiVE

FDA approves Gilead drug in three blood cancers

Zydelig recommended for use in chronic lymphocytic leukaemia and two forms of lymphoma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links